{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parodi Lopez N"],"funding":["Vetenskapsrådet","Swedish Research Council","Swedish state under the agreement between the Swedish government and the county councils (the ALF agreement)"],"pagination":["832-842"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10092534"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["89(2)"],"pubmed_abstract":["<h4>Aims</h4>The aim of this study is to revisit the inter-rater reliability of drug treatment assessments according to the Screening Tool of Older Persons' Prescriptions (STOPP)/Screening Tool to Alert to Right Treatment (START) criteria.<h4>Methods</h4>Potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) were independently identified by two physicians in two cohorts of older people (I: 200 hip fracture patients, median age 85 years, STOPP/START version 1; II: 302 primary care patients, median age 74 years, STOPP/START version 2). Kappa statistics were used to evaluate inter-rater agreement.<h4>Results</h4>In cohort I, a total of 782 PIMs/PPOs, related to 68 (78%) out of 87 criteria, were identified by at least one assessor, 500 (64%) of which were discordantly identified by the assessors, that is, by one assessor but not the other. For four STOPP criteria, all PIMs (n = 9) were concordantly identified. In cohort II, 955 PIMs/PPOs, related to 80 (70%) out of 114 criteria, were identified, 614 (64%) of which were discordantly identified. For three STOPP criteria, all PIMs (n = 3) were concordantly identified. For no START criterion, with ≥1 PPO identified, were all assessments concordant. The kappa value for PIM/PPO identification was 0.52 in both cohorts. In cohort II, the kappa was 0.37 when criteria regarding influenza and pneumococcal vaccines were excluded. Further analysis of discordantly identified PIMs/PPOs revealed methodological aspects of importance, including the data source used and criteria wording.<h4>Conclusions</h4>When the STOPP/START criteria are applied in PIM/PPO research, reliability seems to be an issue not encountered in previous reliability studies."],"journal":["British journal of clinical pharmacology"],"pubmed_title":["Revisiting the inter-rater reliability of drug treatment assessments according to the STOPP/START criteria."],"pmcid":["PMC10092534"],"funding_grant_id":["2021‐01308","2021-01308","521‐2013‐2639","ALFGBG-965025","ALFGBG-716941","521-2013-2639"],"pubmed_authors":["Wallerstedt SM","Belfrage B","Lonnbro J","Koldestam A","Svensson SA","Parodi Lopez N"],"additional_accession":[]},"is_claimable":false,"name":"Revisiting the inter-rater reliability of drug treatment assessments according to the STOPP/START criteria.","description":"<h4>Aims</h4>The aim of this study is to revisit the inter-rater reliability of drug treatment assessments according to the Screening Tool of Older Persons' Prescriptions (STOPP)/Screening Tool to Alert to Right Treatment (START) criteria.<h4>Methods</h4>Potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) were independently identified by two physicians in two cohorts of older people (I: 200 hip fracture patients, median age 85 years, STOPP/START version 1; II: 302 primary care patients, median age 74 years, STOPP/START version 2). Kappa statistics were used to evaluate inter-rater agreement.<h4>Results</h4>In cohort I, a total of 782 PIMs/PPOs, related to 68 (78%) out of 87 criteria, were identified by at least one assessor, 500 (64%) of which were discordantly identified by the assessors, that is, by one assessor but not the other. For four STOPP criteria, all PIMs (n = 9) were concordantly identified. In cohort II, 955 PIMs/PPOs, related to 80 (70%) out of 114 criteria, were identified, 614 (64%) of which were discordantly identified. For three STOPP criteria, all PIMs (n = 3) were concordantly identified. For no START criterion, with ≥1 PPO identified, were all assessments concordant. The kappa value for PIM/PPO identification was 0.52 in both cohorts. In cohort II, the kappa was 0.37 when criteria regarding influenza and pneumococcal vaccines were excluded. Further analysis of discordantly identified PIMs/PPOs revealed methodological aspects of importance, including the data source used and criteria wording.<h4>Conclusions</h4>When the STOPP/START criteria are applied in PIM/PPO research, reliability seems to be an issue not encountered in previous reliability studies.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-05T11:30:04.275Z","creation":"2025-04-05T11:30:04.275Z"},"accession":"S-EPMC10092534","cross_references":{"pubmed":["36098258"],"doi":["10.1111/bcp.15530"]}}